Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial

Authors: Richard G. Langley, Steven R. Feldman, Chenglong Han, Brad Schenkel, Philippe Szapary, Ming-Chun Hsu, Jean-Paul Ortonne, Kenneth B. Gordon, Alexa B. Kimball - Journal of the American Academy of Dermatology 2010 cited by 216